Multidrug-Resistant Transporter Mdr1p-Mediated Uptake of a Novel Antifungal Compound

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2013-09-16

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1128/AAC.01504-13PMID 24041896PMCID PMC3837910
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of novel dietary phytochemicals inhibiting the efflux transporter breast cancer resistance protein (BCRP/ABCG2).

  2013cited by this paper
• Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.

  2013cited by this paper
• Azole Susceptibility and Transcriptome Profiling in Candida albicans Mitochondrial Electron Transport Chain Complex I Mutants

  2012cited by this paper
• Caloric restriction restores the chronological life span of the Goa1 null mutant of Candida albicans in spite of high cell levels of ROS.

  2012cited by this paper
• Global Gene Deletion Analysis Exploring Yeast Filamentous Growth

  2012cited by this paper
• Hidden Killers: Human Fungal Infections

  2012influential reference
• The Monoamine Oxidase A Inhibitor Clorgyline Is a Broad-Spectrum Inhibitor of Fungal ABC and MFS Transporter Efflux Pump Activities Which Reverses the Azole Resistance of Candida albicans and Candida glabrata Clinical Isolates

  2011cited by this paper
• Mitochondria and Fungal Pathogenesis: Drug Tolerance, Virulence, and Potential for Antifungal Therapy

  2011cited by this paper
• Enzymatic Dysfunction of Mitochondrial Complex I of the Candida albicans goa1 Mutant Is Associated with Increased Reactive Oxidants and Cell Death

  2011cited by this paper
• Histatin 5 Uptake by Candida albicans Utilizes Polyamine Transporters Dur3 and Dur31 Proteins*

  2011influential reference
• Regulation of Efflux Pump Expression and Drug Resistance by the Transcription Factors Mrr1, Upc2, and Cap1 in Candida albicans

  2011influential reference
• Emerging opportunistic yeast infections.

  2011cited by this paper
• An insight into the antifungal pipeline: selected new molecules and beyond

  2010cited by this paper
• Genetic Dissection of Azole Resistance Mechanisms in Candida albicans and Their Validation in a Mouse Model of Disseminated Infection

  2010cited by this paper
• Azole Drugs Are Imported By Facilitated Diffusion in Candida albicans and Other Pathogenic Fungi

  2010cited by this paper
• Nosocomial candidemia at a general hospital: prognostic factors and impact of early empiric treatment on outcome (2002-2005).

  2010cited by this paper
• Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature.

  2010cited by this paper
• Methods for using Galleria mellonella as a model host to study fungal pathogenesis.

  2010cited by this paper
• Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease

  2009cited by this paper
• Efflux-Mediated Antifungal Drug Resistance

  2009cited by this paper
• Relative Contributions of the Candida albicans ABC Transporters Cdr1p and Cdr2p to Clinical Azole Resistance

  2009cited by this paper
• Goa1p of Candida albicans Localizes to the Mitochondria during Stress and Is Required for Mitochondrial Function and Virulence

  2009cited by this paper
• The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype

  2008cited by this paper
• Mutations in the multi‐drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole‐resistant Candida albicans strains

  2008influential reference
• Micafungin activity against Candida albicans with diverse azole resistance phenotypes.

  2008cited by this paper
• The Transcription Factor Mrr1p Controls Expression of the MDR1 Efflux Pump and Mediates Multidrug Resistance in Candida albicans

  2007influential reference
• Involvement of Candida albicans pyruvate dehydrogenase complex protein X (Pdx1) in filamentation.

  2007cited by this paper
• Overexpression of the MDR1 Gene Is Sufficient To Confer Increased Resistance to Toxic Compounds in Candida albicans

  2006influential reference
• Signalling and oxidant adaptation in Candida albicans and Aspergillus fumigatus

  2006cited by this paper
• Identification of promoter elements responsible for the regulation of MDR1 from Candida albicans, a major facilitator transporter involved in azole resistance.

  2006cited by this paper
• Evolution of gene families: the multidrug resistance transporter genes in five related yeast species.

  2006influential reference
• Multiple cis-Acting Sequences Mediate Upregulation of the MDR1 Efflux Pump in a Fluconazole-Resistant Clinical Candida albicans Isolate

  2006cited by this paper
• Yeast Model Uncovers Dual Roles of Mitochondria in the Action of Artemisinin

  2005cited by this paper
• A Human-Curated Annotation of the Candida albicans Genome

  2005cited by this paper
• Characteristics of the Polyamine Transporter TPO1 and Regulation of Its Activity and Cellular Localization by Phosphorylation*

  2005cited by this paper
• Evolution of antifungal-drug resistance: mechanisms and pathogen fitness

  2005cited by this paper
• Multidrug Pump Inhibitors Uncover Remarkable Activity of Plant Antimicrobials

  2002cited by this paper
• Involvement of Candida albicans NADH dehydrogenase complex I in filamentation.

  2002cited by this paper
• Resistance Mechanisms in Clinical Isolates of Candida albicans

  2002cited by this paper
• Evolution of drug resistance in Candida albicans.

  2002cited by this paper
• Population genomics of drug resistance in Candida albicans

  2002cited by this paper
• Estimating the cost of nosocomial candidemia in the united states.

  2001cited by this paper
• In search of natural substrates and inhibitors of MDR pumps.

  2001cited by this paper
• Is vancomycin resistance in enterococci predictive of inferior outcome of enterococcal bacteremia?

  2001cited by this paper
• Targeted gene disruption in Candida albicans wild‐type strains: the role of the MDR1 gene in fluconazole resistance of clinical Candida albicans isolates

  2000cited by this paper
• Polyamine transport in bacteria and yeast.

  1999cited by this paper
• Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance

  1998cited by this paper
• Multiple Molecular Mechanisms Contribute to a Stepwise Development of Fluconazole Resistance in Clinical Candida albicans Strains

  1998cited by this paper
• The STK2 gene, which encodes a putative Ser/Thr protein kinase, is required for high-affinity spermidine transport in Saccharomyces cerevisiae

  1997cited by this paper
• Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus

  1997cited by this paper
• Isogenic strain construction and gene mapping in Candida albicans.

  1993cited by this paper

• Discovery and Structural Optimization of Spirodioxynaphthalene-Based Mdr1 Efflux Pump Inhibitor to Combat Azole Resistance in Candida albicans.

  2026cites this paper
• Exporter Mdr1 as an importer is an achilles' heel for combating drug-resistant Candida.

  2026cites this paper
• Comprehensive Insights into Sugar Transporters of Candidozyma auris and Their Roles in Antifungal Resistance.

  2026cites this paper
• Alternaria alternata botybirnavirus 1 (AaBRV1) Infection Affects the Biological Characteristics of Its Host Fungus Alternaria alternata

  2025cites this paper
• Repurposing Plant-Based Histone Acetyltransferase Inhibitors: A Review of Novel Therapeutic Strategies Against Drug-Resistant Fungal Biofilms

  2024cites this paper
• Anti-fungal peptides: an emerging category with enthralling therapeutic prospects in the treatment of candidiasis

  2024cites this paper
• The Light-activated Effect of Natural Anthraquinone Parietin against Candida auris and Other Fungal Priority Pathogens

  2023cites this paper
• The Transporter-Mediated Cellular Uptake and Efflux of Pharmaceutical Drugs and Biotechnology Products: How and Why Phospholipid Bilayer Transport Is Negligible in Real Biomembranes

  2021cites this paper
• Fungal Biofilms as a Valuable Target for the Discovery of Natural Products That Cope with the Resistance of Medically Important Fungi—Latest Findings

  2021cites this paper
• Inhibition of Mitochondrial Complex III in Candida Albicans ADH1 Deletion Mutant Attenuates Its Pathogenicity Significantly

  2021cites this paper
• Berberine reverses multidrug resistance in Candida albicans by hijacking the drug efflux pump Mdr1p

  2020cites this paper
• Carrier-Mediated Drug Uptake in Fungal Pathogens

  2020influential citation
• Computational Studies of Drug Repurposing Targeting P-Glycoprotein-Mediated Multidrug Resistance Phenotypes in Priority Infectious Agents

  2020cites this paper
• Anticandidal agent for multiple targets: the next paradigm in the discovery of proficient therapeutics/overcoming drug resistance.

  2019cites this paper
• Targeting Candida spp. to develop antifungal agents.

  2018cites this paper
• Echinocandins in antifungal pharmacotherapy

  2017cites this paper
• A New Natural Product Analog of Blasticidin S Reveals Cellular Uptake Facilitated by the NorA Multidrug Transporter

  2017cites this paper
• Exploiting mitochondria as targets for the development of new antifungals

  2017cites this paper
• Repurposing an inhibitor of ribosomal biogenesis with broad anti-fungal activity

  2017cites this paper
• Functional diversity of complex I subunits in Candida albicans mitochondria

  2016cites this paper
• pHluorin enables insights into the transport mechanism of antiporter Mdr1: R215 is critical for drug/H+ antiport.

  2016cites this paper
• Biological Characterization and in Vivo Assessment of the Activity of a New Synthetic Macrocyclic Antifungal Compound.

  2016cites this paper
• Energy coupling mechanisms of MFS transporters

  2015cites this paper
• The molecular mechanism of azole resistance in Aspergillus fumigatus: from bedside to bench and back

  2015cites this paper
• Therapeutic drug monitoring of intracellular anti-infective agents.

  2014cites this paper
• The Problem of Microbial Drug Resistance

  2014cites this paper
• 1 The Problem of Microbial Drug Resistance

  2014cites this paper
• Antifungal drug discovery: the process and outcomes.

  2014cites this paper